Stockscreener 앱 받기
0.3764
3.98%
-0.0285
전일 마감가:
$0.4049
열려 있는:
$0.3806
하루 거래량:
54,595
Relative Volume:
0.02
시가총액:
$9.63M
수익:
-
순이익/손실:
$-29.80M
주가수익비율:
-0.3163
EPS:
-1.19
순현금흐름:
$-25.19M
1주 성능:
+1.78%
1개월 성능:
-23.51%
6개월 성능:
-34.55%
1년 성능:
-61.88%
1일 변동 폭
$0.3756
$0.4044
1주일 범위
$0.3301
$0.4093
52주 변동 폭
$0.25
$1.94
센세이 바이오테라 Stock (SNSE) Company Profile
명칭
Sensei Biotherapeutics Inc
전화
(240) 243-8000
주소
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
SNSE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
0.3764 | 9.63M | 0 | -29.80M | -25.19M | -1.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.56 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.21 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.82 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.05 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.19 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
센세이 바이오테라 Stock (SNSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-06-29 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2021-03-01 | 개시 | Citigroup | Buy |
| 2021-03-01 | 개시 | Oppenheimer | Outperform |
| 2021-03-01 | 개시 | Piper Sandler | Overweight |
모두보기
센세이 바이오테라 주식(SNSE)의 최신 뉴스
SEC Form DEF 14A filed by Sensei Biotherapeutics Inc. - Quantisnow
Penny Stocks To Add to Your WatchlistMarch 30th - MarketBeat
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - The Manila Times
Promising Penny Stocks To ResearchMarch 29th - MarketBeat
Best Penny Stocks To Follow NowMarch 28th - MarketBeat
Sensei Biotherapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Sensei Biotherapeutics stock hits 52-week low at $0.34 - Investing.com
HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE) - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer - Armenian Reporter
Sensei Biotherapeutics Reports Promising 2024 Results - TipRanks
Sensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves - GuruFocus
Sensei stock holds Buy rating, $4 target from H.C. Wainwright By Investing.com - Investing.com Australia
Sensei Rockets on FY ’24 Results - Baystreet.ca
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga
Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer - TipRanks
Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating - Marketscreener.com
Sensei Biotherapeutics reports FY24 EPS ($1.20) vs ($1.22) last year - TipRanks
Sensei stock holds Buy rating, $4 target from H.C. Wainwright - Investing.com
Sensei Biotherapeutics Inc Cash Runway Into Q2 Of 2026 - MarketScreener
Sensei Biotherapeutics, Inc. SEC 10-K Report - TradingView
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - GlobeNewswire
Breakthrough: Sensei's Cancer Drug Triples Response Rate in Hard-to-Treat Tumors - Stock Titan
Sensei Biotherapeutics announces initial results from solnerstotug trial portion - TipRanks
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data For Solnerstotug In PD-(L)1 Resistant Tumors - Marketscreener.com
Sensei Biotherapeutics : Company Presentation March 2025 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors - GlobeNewswire
Revolutionary Cancer Treatment Triples Response Rate in Hard-to-Treat Tumors: Clinical Trial Results Revealed - Stock Titan
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Drop in Short Interest - Defense World
Sensei Biotherapeutics Stock Price, Quotes and Forecasts | NASDAQ:SNSE - Benzinga
Sensei Biotherapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Sensei Biotherapeutics (SNSE) to Release Quarterly Earnings on Wednesday - Defense World
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock - MSN
A stock that deserves closer examination: Sensei Biotherapeutics Inc (SNSE) - US Post News
Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Manila Times
Biotech Spotlight: Sensei Bio Takes Center Stage at Major Healthcare Conference - StockTitan
Sensei Biotherapeutics, Inc. Appoints Robert Pierce as Chief Scientific Officer; Opens its Boston Office - Marketscreener.com
Sensei Biotherapeutics Inc Shares Rise 25.49% From The Lows – But Will They Continue? - Marketing Sentinel
Biotech Advances Breakthrough Cancer Treatment Results - Streetwise Reports
Sensei Biotherapeutics (NASDAQ:SNSE) Earns Buy Rating from HC Wainwright - Defense World
Sensei Biotherapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Australia
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones - The Manila Times
Sensei Bio's Cancer Drug Shows Promise in Phase 1/2 Trial, Enrolls 45 Patients for VISTA Study - StockTitan
Sensei Biotherapeutics faces Nasdaq delisting risk - Investing.com
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - GlobeNewswire
Sensei Biotherapeutics Q3 2024 Results and Strategic Moves - TipRanks
센세이 바이오테라 (SNSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
자본화:
|
볼륨(24시간):